JP2021534202A - 眼科疾患を処置する為の薬物の為の方法及び組成物 - Google Patents

眼科疾患を処置する為の薬物の為の方法及び組成物 Download PDF

Info

Publication number
JP2021534202A
JP2021534202A JP2021509910A JP2021509910A JP2021534202A JP 2021534202 A JP2021534202 A JP 2021534202A JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021509910 A JP2021509910 A JP 2021509910A JP 2021534202 A JP2021534202 A JP 2021534202A
Authority
JP
Japan
Prior art keywords
subject
formula
camkk2
disease
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021509910A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020041344A5 (https=
JP2021534202A5 (https=
Inventor
カズンズ，スコット，ダブリュ．
メッツ，プリヤタム，エス．
グッデン，デイヴィッド，エム．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2021534202A publication Critical patent/JP2021534202A/ja
Publication of JPWO2020041344A5 publication Critical patent/JPWO2020041344A5/ja
Publication of JP2021534202A5 publication Critical patent/JP2021534202A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2021509910A 2018-08-20 2019-08-20 眼科疾患を処置する為の薬物の為の方法及び組成物 Pending JP2021534202A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862719938P 2018-08-20 2018-08-20
US62/719,938 2018-08-20
PCT/US2019/047309 WO2020041344A1 (en) 2018-08-20 2019-08-20 Methods and compositions for drugs to treat ophthalmic diseases

Publications (3)

Publication Number Publication Date
JP2021534202A true JP2021534202A (ja) 2021-12-09
JPWO2020041344A5 JPWO2020041344A5 (https=) 2022-08-26
JP2021534202A5 JP2021534202A5 (https=) 2022-08-26

Family

ID=69591159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021509910A Pending JP2021534202A (ja) 2018-08-20 2019-08-20 眼科疾患を処置する為の薬物の為の方法及び組成物

Country Status (14)

Country Link
US (2) US12221447B2 (https=)
EP (1) EP3840745A4 (https=)
JP (1) JP2021534202A (https=)
KR (1) KR20210049857A (https=)
CN (1) CN112654353A (https=)
AU (1) AU2019326448A1 (https=)
BR (1) BR112021003189A2 (https=)
CA (1) CA3109809A1 (https=)
CO (1) CO2021003607A2 (https=)
IL (1) IL280952A (https=)
MX (1) MX2021002028A (https=)
SG (1) SG11202101522WA (https=)
TW (1) TW202021968A (https=)
WO (1) WO2020041344A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) * 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なＣａＭＫＫ阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0600763D0 (en) 2006-01-13 2006-02-22 Crysoptix Ltd 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof
GB0600764D0 (en) * 2006-01-13 2006-02-22 Crysoptix Ltd Organic compound, optical crystal film and method of production thereof
US8207185B2 (en) 2006-10-12 2012-06-26 Duke University CaMKKβ as a target for treating obesity
JP5464395B2 (ja) 2008-02-01 2014-04-09 大陽日酸株式会社 重水素化された芳香環又は複素環を有する化合物の製造方法
WO2009154754A2 (en) 2008-06-17 2009-12-23 Concert Pharmaceuticals, Inc. Synthesis of deuterated morpholine derivatives
WO2010033511A1 (en) 2008-09-16 2010-03-25 Concert Pharmaceuticals, Inc. Deuterated 2-amino-3-hydroxypropanoic acid derivatives
WO2012024255A2 (en) 2010-08-16 2012-02-23 Duke University Camkk-beta as a target for treating cancer
WO2012064618A1 (en) * 2010-11-09 2012-05-18 Crysoptix Kk Negative dispersion retardation plate and achromatic circular polarizer
CN103702961A (zh) 2011-05-23 2014-04-02 赛诺菲 含有n-烷基的氘代化合物的制备方法
CN104684555A (zh) 2012-09-18 2015-06-03 奥斯拜客斯制药有限公司 囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
EP2935251A1 (en) 2012-12-20 2015-10-28 Concert Pharmaceuticals Inc. Deuterated alk inhibitors
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
RU2675270C2 (ru) 2013-10-17 2018-12-18 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
AU2019326448A1 (en) 2018-08-20 2021-03-11 Duke University Methods and compositions for drugs to treat ophthalmic diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003012516A (ja) * 2001-04-25 2003-01-15 Sumitomo Pharmaceut Co Ltd 新規なＣａＭＫＫ阻害剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"CAS REGISTRY No. 688792-55-4等", DATABASE REGISTRY [ONLINE], JPN7023003150, 3 June 2004 (2004-06-03), ISSN: 0005232201 *
"PUBCHEM CID 6618466", CREATE DATE: 2006年6月5日, JPN6023034072, 5 June 2006 (2006-06-05), ISSN: 0005232203 *
"PUBCHEM CID 91522194", CREATE DATE: 2015年3月17日, JPN6023034071, 17 March 2015 (2015-03-17), ISSN: 0005232202 *
IVACHTCHENKO, A. V. ET AL.: ""Synthesis of Substituted 4-Oxo-2-thioxo-1,2,3,4-tetrahydroquinazolines and 4-Oxo-3,4-dihydroquinaz", JOURNAL OF COMBINATORIAL CHEMISTRY, vol. 5, no. 6, JPN6023034074, 16 August 2003 (2003-08-16), pages 775 - 788, XP003013711, ISSN: 0005232205, DOI: 10.1021/cc020097g *
MAI, S. ET AL.: ""Diversity-oriented synthesis of imidazo[2,1-a]isoquinolines"", CHEMICAL COMMUNICATIONS, vol. 54, no. 73, JPN6023034073, 19 July 2018 (2018-07-19), pages 10240 - 10243, XP055900320, ISSN: 0005232204, DOI: 10.1039/C8CC05390A *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024257328A1 (ja) * 2023-06-16 2024-12-19 千寿製薬株式会社 眼疾患モデル動物
JPWO2024257328A1 (https=) * 2023-06-16 2024-12-19
JP7706671B2 (ja) 2023-06-16 2025-07-11 千寿製薬株式会社 眼疾患モデル動物
JP7776899B1 (ja) * 2024-06-14 2025-11-27 株式会社坪田ラボ 局所投与用の重症眼表面疾患の処置剤

Also Published As

Publication number Publication date
WO2020041344A4 (en) 2020-03-26
WO2020041344A1 (en) 2020-02-27
KR20210049857A (ko) 2021-05-06
MX2021002028A (es) 2021-07-21
SG11202101522WA (en) 2021-03-30
CA3109809A1 (en) 2020-02-27
BR112021003189A2 (pt) 2021-05-11
EP3840745A1 (en) 2021-06-30
US12221447B2 (en) 2025-02-11
AU2019326448A1 (en) 2021-03-11
IL280952A (en) 2021-04-29
EP3840745A4 (en) 2022-06-08
CN112654353A (zh) 2021-04-13
CO2021003607A2 (es) 2021-07-30
US20210198266A1 (en) 2021-07-01
US20250122209A1 (en) 2025-04-17
TW202021968A (zh) 2020-06-16

Similar Documents

Publication Publication Date Title
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
RU2557982C2 (ru) Композиции и способы ингибирования пути jak
EP2651403B1 (en) Use of lp-pla2 inhibitors in the treatment and prevention of eye diseases
JP6250728B2 (ja) α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法
JP2000514402A (ja) Ｖｅｇｆに関連する目の病気に関する治療処置
US20100004244A1 (en) Use of cb2 receptor agonists for promoting neurogenesis
CN109069461A (zh) 与髓源性抑制细胞相关的病症的治疗方法
Pan et al. Baicalein—A potent pro-homeostatic regulator of microglia in retinal ischemic injury
Hunziker et al. Synthesis, characterization, and in vivo evaluation of a novel potent autotaxin-inhibitor
US10537563B2 (en) Methods for treating ocular disease using inhibitors of CSF-1R
Li et al. Development of nitric oxide-donating netarsudil derivatives as a synergistic therapy for glaucoma with reduced ocular irritation
JP2023506118A (ja) 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
JP2016506931A (ja) 点眼用組成物
WO2024029597A1 (ja) ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
WO2010056710A1 (en) Compositions and methods for treating eye diseases
JP2014511392A (ja) 創傷を治癒または治療するための分子標的
CN120754133B (zh) Ber-ApoEVs及其制备和应用
Hunziker et al. Synthesis, Characterization, and in vivo Evaluation of a Novel Potent Autotaxin-Inhibitor. Front. Pharmacol. 12: 699535. doi: 10.3389/fphar. 2021.699535
Ke et al. Autophagy-Induced Microglial Death Contributes to Neuroinflammation in Acute Optic Nerve Injury
KR20250149620A (ko) 경공막 경로를 통해 망막에 전달되는 약물이 담지된 세포외 소포체 및 이를 포함하는 시신경변성질환 예방 또는 치료용 조성물
CN118304286A (zh) 芥子碱硫氰酸盐在制备治疗视网膜新生血管相关疾病的药物中的应用
WO2021163304A1 (en) Activation of neuropeptide receptors on plasmacytoid dendritic cells to treat or prevent ocular diseases associated with neovascularization and inflammation
Gui et al. Non‐invasive and efficient diabetic retinal mitochondrial repair nanoplatform based on engineered endothelial mitochondrial‐derived vesicles with dynamic integrated stress response modulation
Shosha Neurovascular Degeneration Following Retinal Ischemia Reperfusion Injury: Role of Arginase 2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240730